THANK YOU FOR SUBSCRIBING
Biotech startups are on the rise, and a slew of challenges come with that. For many startups, the biggest challenge is simply finding a way to get the technology they've developed to market.
FREMONT, CA: Tiny molecule medicines aimed at the masses have been the focus of drug development for the past century. The reason it didn't work in some cases was apparent but not in others. Human genetics became more understood at the turn of the century-the aspects of lives that make people unique. Biotech drugs allow researchers to make personalized medicines using human genetics. Medications are changing, like how the internet has changed lives so far.
Investors continue to shower the biotech business with billions of dollars as it produces life-saving pharmaceuticals. Biotechnology has contributed to the success of efforts to improve people's health and meet the growing demand for food.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Despite the growth of the biotechnology industry, this field faces significant obstacles:
High Degrees of Danger: Typically, biotech firms receive patent protection for their products, allowing them to recover their research and development costs while gaining a market advantage. After the patent protection period expires, their market position is more established than their competitors. This provides the potential for enormous returns. However, investors must measure the potential for enormous returns that these companies offer against the abundance of enormous risks. First, there is a lengthy period of development during which money is spent on R&D to launch a successful product. For instance, the cost of developing a drug could reach a billion dollars. And to sell their medications on the market, biotech companies must obtain FDA approval, which is a complex and time-consuming process.
In addition to human testing, there are extensive trials, with the FDA maintaining a close eye on each stage. Occasionally, during these evaluations, the product may prove to be untenable. The whole process could take up to a decade, during which the company will incur losses on the product. During the R&D phase, there could be significant technological changes that have a negative impact on the product.
In addition, analysts need help accurately valuing biotech companies due to their exposure to hazardous development processes. This is a significant reason why biotech company equities are so volatile. Even if the biotech company can market its product, there is still the risk of how well the market will receive it and the possibility of litigation risks if any adverse effects arise as people begin using the product.
Affordability: The escalating expense of healthcare, specifically the cost of drugs, will continue to be a political hot potato. No matter what the FDA may try or say, a substantial portion of the public, their legislatures, and federal representatives do not appear to believe the pharmaceutical industry's argument that current prices fund R&D and that price controls could eventually impede R&D. When the value of exorbitant biotechnology treatments for severe diseases is debated, it is probable that the concerns will intensify.
A common medication used to treat cholesterol may cost approximately $1,825 per year or $5 per day. Compare this to a biotech drug that costs $20,000 per year or something more expensive.
This could put purchasers and participants on the defensive as they compete to determine the appropriate cost-sharing. Employers and insurers must balance actuarial concerns, hazards of patient non-adherence, and the possibility of inaccurate clinical results when making coverage decisions. What occurs when a patient cannot afford the additional costs of a particular treatment? What happens when a patient's insurance benefits for an expensive chronic therapy are exhausted? What if an insurer excludes a biotechnology drug from its formulary due to its high acquisition cost? These occurrences may not be typical, but their probability alarms many experts who perceive a fundamental conflict between profits and patients.
More in News